98%
921
2 minutes
20
Genetic intra-tumor heterogeneity is a universal property of all cancers. It emerges from the interplay of cell division, mutation accumulation, and selection with important implications for the evolution of treatment resistance. Theoretical and data-driven approaches extensively studied intra-tumor heterogeneity in ageing somatic tissues or cancers at detection. Yet, the expected patterns of intra-tumor heterogeneity during and after treatment are less well understood. Here, we use stochastic birth-death processes to investigate the expected patterns of intra-tumor heterogeneity across different treatment scenarios. We consider homogeneous treatment response with shrinking, growing, and stable disease, and follow-up investigating heterogeneous treatment response with sensitive and resistant cell types. We derive analytic expressions for the site frequency spectrum, the total mutational burden and the single-cell mutational burden distribution that we validate with computer simulations. We find that the site frequency spectrum after homogeneous treatment response retains its characteristic power-law tail, while emergent resistant clones cause peaks corresponding to their sizes. The frequency of the largest resistant clone is subdominant and independent of the population size at detection, whereas the relative total number of resistant cells increases with detection size. Furthermore, the growth dynamics under treatment determine whether the total mutational burden is dominated by preexisting or newly acquired mutations, suggesting different possible treatment strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341898 | PMC |
http://dx.doi.org/10.1093/genetics/iyaf101 | DOI Listing |
Lab Invest
September 2025
Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. Electronic address:
The BRAFV600E mutation test for melanoma patients has become the key to precision therapy.Comparing the concordance of immunohistochemistry (IHC), quantitative real-time polymerase chain reaction (qPCR), and next-generation sequencing (NGS) in detecting the BRAFV600E mutation in a Chinese melanoma patient population. In addition, evaluating BRAFV600E mutation heterogeneity between primary and metastatic melanoma sites and within the same lesion, and investigating the association between BRAFV600E mutation status and tumor cell morphology.
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Biomedical Engineering, College Station, TX 77843.
Tumor-immune interactions are central to cancer progression and treatment response, driving cell death through immune-mediated killing and resource-limited competition. In early-stage disease or following effective treatment, cancer populations are often small and difficult to observe directly. Disease monitoring therefore relies on the detection of biomarkers such as circulating tumor DNA (ctDNA) as noisy proxies to cancer size.
View Article and Find Full Text PDFJ Clin Med
August 2025
Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
Inter- or intra-tumor heterogeneity refers to the genetic, epigenetic, and phenotypic variability that characterizes tumor cells. Regardless of its nature, this complexity represents a great challenge for diagnosis and treatment, since cells with different characteristics may respond differently to therapies, resulting in drug resistance and/or relapses. Furthermore, it has emerged that this heterogeneity can change over time or following a stimulus, such as a treatment.
View Article and Find Full Text PDFMod Pathol
August 2025
Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université Paris Cité, Personalized Medicine, Pharmacogenomics and Therapeutic Optimization, Paris, France; Institut du cancer Paris CARPEM, APHP, department of Genomic Medicine of tumors and cancers, APHP.Centre, Paris France. Elec
Colon cancer (CC) is the third most prevalent cancer type. It is highly heterogeneous, particularly in terms of molecular profiles, which have both prognostic and predictive impacts on the treatment efficacy. However, CC treatment in adjuvant situations is currently guided solely by T and N staging.
View Article and Find Full Text PDFDiscov Oncol
August 2025
Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, China.
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide, often diagnosed at advanced stages with limited treatment options. Despite advancements in systemic therapies, including the use of lenvatinib, the survival rate for advanced HCC remains low due to drug resistance and tumor heterogeneity.
Method: This study employed single-cell sequencing and spatial transcriptomics to investigate intra-tumor heterogeneity and identify subpopulations of malignant cells with inherent drug resistance.